Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2780506 | 0.81 | TSHR (0.46) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL2026871 | 0.80 | TSHR (0.50) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL14769157 | 0.77 | TP53 (0.46) | TSHRTP53TDP1PPARDACHE | |
| SCHEMBL4060148 | 0.77 | TSHR (0.52) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL575207 | 0.77 | TSHR (0.52) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL7613774 | 0.75 | PPARD (0.54) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL2874004 | 0.75 | TSHR (0.44) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL29739400 | 0.73 | TSHR (0.48) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL21428725 | 0.73 | TSHR (0.48) | TSHRTP53TDP1PPARDMEN1 | |
| SCHEMBL10509700 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-20170101429-A1 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| US-20170081346-A1 | MESOSCOPIC MATERIALS COMPRISED OF ORDERED SUPERLATTICES OF MICROPOROUS METAL-ORGANIC FRAMEWORKS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-03-23 | — | — | US | disclosed |
| US-20150360964-A1 | ZEOLITE COMPOSITIONS AND METHODS FOR TAILORING ZEOLITE CRYSTAL HABITS WITH GROWTH MODIFIERS | UNIVERSITY OF HOUSTON SYSTEM | 2015-12-17 | — | — | US | disclosed |
| US-9034851-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8933116-B2 | Gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2809691-A1 | BLOCK COPOLYMER, PROCESS AND COMPOSITION | DSM IP Assets B.V. (NL) | 2014-12-10 | — | — | EP | disclosed |
| WO-2014150712-A1 | DUAL CURE COMPOSITE RESINS CONTAINING URETDIONE AND USATURATED SITES | BAYER MATERIAL SCIENCE LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140235583-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2014-08-21 | — | — | US | disclosed |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2013113930-A1 | BLOCK COPOLYMER, PROCESS AND COMPOSITION | DSM IP ASSETS B.V. (NL) | 2013-08-08 | — | — | WO | disclosed |
| US-20120202006-A1 | ZEOLITE COMPOSITIONS AND METHODS FOR TAILORING ZEOLITE CRYSTAL HABITS WITH GROWTH MODIFIERS | UNIVERSITY OF HOUSTON (US) | 2012-08-09 | — | — | US | disclosed |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2010-12-09 | — | — | US | disclosed |
| EP-1776399-A1 | MONODISPERSE POLYMERS CONTAINING (ALKYL)ACRYLIC ACID MOIETIES, PRECURSORS AND METHODS FOR MAKING THEM AND THEIR APPLICATIONS | UNIVERSITEIT GENT (BE) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006002496-A1 | MONODISPERSE POLYMERS CONTAINING (ALKYL)ACRYLIC ACID MOIETIES, PRECURSORS AND METHODS FOR MAKING THEM AND THEIR APPLICATIONS | UNIVERSITEIT GENT (BE) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235583-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | TSHR 2794/4885TP53 692/4885TDP1 1525/4885 |
| US-20170081346-A1 | MESOSCOPIC MATERIALS COMPRISED OF ORDERED SUPERLATTICES OF MICROPOROUS METAL-ORGANIC FRAMEWORKS | MCM2, YTHDF2, MCM6 | TSHR 4868/4885TP53 1673/4885TDP1 3932/4885 |
| US-20170101429-A1 | METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS | EPCAM, SOD1, SBDS | TSHR 4014/4885TP53 517/4885TDP1 2365/4885 |
| US-20140018342-A1 | GAMMA SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | TSHR 4499/4885TP53 1671/4885TDP1 293/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | TSHR 1934/4885TP53 1996/4885TDP1 4658/4885 |
| US-20100311694-A1 | Set of Geldanamycin Derivatives and Their Preparation Methods | HSP90AA1, HSP90AB1, HSP90B1 | TSHR 4771/4885TP53 736/4885TDP1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.